Adjuvant treatment with recombinant interferon-alpha 2a in patients operated for cutaneous melanoma: A pilot study

C. Nunziata, F. Concolino, S. Gilberti, E. Pagani, C. Ricci, L. Nardini, D. Cantagallo, E. Bonmassar, F. Atzori

Research output: Contribution to journalArticle

Abstract

Twenty-five patients resected for cutaneous melanoma (stage I and stage II), were subjected to a pilot study of post-surgery adjuvant therapy with recombinant interferon-alpha-2a (IFN, 3 MU/sqm im, every other day, 3 times/week, 4 weeks being considered a 'treatment cycle') for 2 years. The treatment was well tolerated with limited fever and flu-like syndrome, easily controlled by paracetamol. Detailed toxicological analysis pointed out that the treatment produced modest and reversible increase of transaminases, significant decline of white blood cells (WBC) and platelets, not reaching however levels requiring dose reduction or treatment suspension. Reduced WBC count was due mainly to polymorphonucleate down regulation, whereas little reduction of lymphocyte, and modest but significant increase of monocytes during the first treatment cycle was observed. These results support the hypothesis that long-term treatment with low-dose IFN is well tolerated and could be applied safely to patients with limited risk of melanoma recurrence or metastasis.

Original languageEnglish
Pages (from-to)167-172
Number of pages6
JournalChronica Dermatologica
Volume7
Issue number2
Publication statusPublished - 1997

Keywords

  • adjuvant therapy
  • interferon-alpha-2a
  • melanoma

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Adjuvant treatment with recombinant interferon-alpha 2a in patients operated for cutaneous melanoma: A pilot study'. Together they form a unique fingerprint.

  • Cite this

    Nunziata, C., Concolino, F., Gilberti, S., Pagani, E., Ricci, C., Nardini, L., Cantagallo, D., Bonmassar, E., & Atzori, F. (1997). Adjuvant treatment with recombinant interferon-alpha 2a in patients operated for cutaneous melanoma: A pilot study. Chronica Dermatologica, 7(2), 167-172.